Immuncell-LC

BIOLOGICAL6 trials

Sponsors

GC Cell Corporation

Conditions

Advanced Hepatocellular CarcinomaCarcinoma, HepatocellularHepatocellular CarcinomaLiver TransplantationPancreatic Ductal Adenocarcinoma

Phase 1

Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

CompletedNCT03983967

GC Cell CorporationLiver Transplantation

Start: 2019-01-24End: 2022-08-30Updated: 2023-06-22

Phase 2

Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC

CompletedNCT01897610

GC Cell CorporationAdvanced Hepatocellular Carcinoma

Start: 2013-12-31End: 2017-07-04Updated: 2023-06-26

Safety and Efficacy of Immuncell-LC in TACE Therapy

CompletedNCT02856815

GC Cell CorporationCarcinoma, Hepatocellular

Start: 2018-05-28End: 2022-09-22Updated: 2023-06-22

Phase 3

Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients

CompletedNCT00699816

GC Cell CorporationHepatocellular Carcinoma

Start: 2008-07-31End: 2012-11-30Updated: 2023-07-11

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

RecruitingNCT04969731

GC Cell CorporationPancreatic Ductal Adenocarcinoma

Start: 2021-09-07End: 2027-06-30Target: 408Updated: 2021-11-22

Unknown Phase

Retrospective Study of Long-Term Survival of Immuncell-LC in Patients Undergoing Curative Resection for HCC in Korea

CompletedNCT06620510

GC Cell CorporationHepatocellular Carcinoma

Start: 2024-09-30End: 2025-06-13Updated: 2025-08-15

Related Papers

Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.

2015-03-04379 citations